Phase
Condition
N/ATreatment
Placebo
Pioglitazone
Clinical Study ID
Ages 35-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
CKD patients classified as Stage 3 and 4 of National Kidney FoundationClassification with estimated glomerular filtration rate (GFR) between 15 and 59mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formulabased on serum creatinine, age, gender, and race.
Men and women 35 to 70 years of age
Exclusion
Exclusion Criteria:
Allergy to Glitazones
Myocardial infarction
Heart failure
Angina
History of kidney stones
Liver disease (abnormal liver enzymes)
Anemia (hemoglobin <8 g/dl)
Cancer with current treatment
Previous organ transplantation
Immunosuppressant therapy
Human immunodeficiency virus infection
Pregnancy or lactating
Current tobacco use
Dilantin and oral contraceptive usage due to potential drug interaction withglitazones
Self-identified history of hypoglycemia
Study Design
Study Description
Connect with a study center
University of Texas at Arlington
Arlington, Texas 76010
United StatesActive - Recruiting
UT Southwestern
Dallas, Texas 75390
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.